News Sentiment

AMRN sentiment intelligence

Amarin Corporation PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 14.88 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-9.1% over one week, -2.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -9.1% Price reacting lower
Trend fit Trend active -2.4% over four weeks
Fair value -1.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 17
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 6
Seeking Alpha 3
Finviz 3
JD Supra 2
The National Law Review 2
MSN 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 11
Regulatory and legal 4
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-43 of 43
NPR Direct company coverage

How a Supreme Court fight over fish oil could raise your prescription drug costs

The Supreme Court is hearing the case of Hikma v. Amarin, which could significantly impact the cost of prescription drugs. The dispute revolves around "skinny labeling," a strategy allowing generic drugs to enter the market faster for unpatented uses. A ruling against generic dru

Tone
Neutral 50/100
Event
Market update
Published
29 Apr 2026 18:09
Source
NPR
Quiver Quantitative Direct company coverage

AMARIN ($AMRN) Releases Q1 2026 Earnings | AMRN Stock News

AMARIN ($AMRN) reported its Q1 2026 earnings, missing earnings per share estimates but beating revenue expectations. The company posted -$0.09 EPS on revenue of $45,130,000. Institutional investors showed mixed activity, with 31 adding and 34 decreasing their positions in AMARIN

Tone
Negative 40/100
Event
Earnings
Published
29 Apr 2026 12:55
Source
Quiver Quantitative
Investing.com Direct company coverage

Earnings call transcript: Amarin Q1 2026 shows revenue growth amid restructuring

Amarin Corporation (AMRN) reported strong Q1 2026 results, with total net revenue increasing by 7.4% year-over-year to $45.1 million, driven by strategic restructuring and international partnerships. The company significantly reduced operating expenses by 31%, narrowing its opera

Tone
Positive 75/100
Event
Earnings
Published
29 Apr 2026 12:39
Source
Investing.com
kens5.com Direct company coverage

Amarin: Q1 Earnings Snapshot

Amarin Corp. PLC (AMRN) reported a first-quarter loss of $10.5 million, or 60 cents per share. After adjustments for restructuring and non-recurring costs, the loss was 9 cents per share. The biopharmaceutical company recorded revenues of $45.1 million for the period, and its sto

Tone
Negative 37/100
Event
Earnings
Published
29 Apr 2026 12:39
Source
kens5.com